Missing/wrong data?
Log in to edit
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
scientific article
Author/s
author: Lance Miller, Heidi D Klepin, Boris Pasche, Ralph B. D'Agostino Jr, Timothy S Pardee
Work details
Publication date
May 8, 2017
-
-
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.